Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab
10.1038/onc.2008.394
Crossref journal-article
Springer Science and Business Media LLC
Oncogene (297)
Bibliography

Pickl, M., & Ries, C. H. (2008). Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab. Oncogene, 28(3), 461–468.

Authors 2
  1. M Pickl (first)
  2. C H Ries (additional)
References 32 Referenced 330
  1. Engelman JA, Lee RJ, Karnezis A, Bearss DJ, Webster M, Siegel P et al. (1998). Reciprocal regulation of neu tyrosine kinase activity and caveolin-1 protein expression in vitro and in vivo. Implications for human breast cancer. J Biol Chem 273: 20448–20455. (10.1074/jbc.273.32.20448) / J Biol Chem by JA Engelman (1998)
  2. Guo H, Wei B, Zhang HY, Liu GJ, Bu H, Lang ZQ et al. (2005). [HER2 expression and its prognostic implication in lymph node negative breast carcinoma: a meta-analysis]. Zhonghua Bing Li Xue Za Zhi 34: 140–146. / Zhonghua Bing Li Xue Za Zhi by H Guo (2005)
  3. Hudis CA . (2007). Trastuzumab—mechanism of action and use in clinical practice. N Engl J Med 357: 39–51. (10.1056/NEJMra043186) / N Engl J Med by CA Hudis (2007)
  4. Hudziak RM, Lewis GD, Winget M, Fendly BM, Shepard HM, Ullrich A . (1989). p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 9: 1165–1172. (10.1128/MCB.9.3.1165) / Mol Cell Biol by RM Hudziak (1989)
  5. Jung J-H, Traugh JA . (2005). Regulation of the interaction of Pak2 with Cdc42 via autophosphorylation of serine 141. J Biol Chem 280: 40025–40031. (10.1074/jbc.M509075200) / J Biol Chem by J-H Jung (2005)
  6. Kwon T, Kwon DY, Chun J, Kim JH, Kang SS . (2000). Akt protein kinase inhibits Rac1-GTP binding through phosphorylation at serine 71 of Rac1. J Biol Chem 275: 423–428. (10.1074/jbc.275.1.423) / J Biol Chem by T Kwon (2000)
  7. Lee GY, Kenny PA, Lee EH, Bissell MJ . (2007). Three-dimensional culture models of normal and malignant breast epithelial cells. Nat Methods 4: 359–365. (10.1038/nmeth1015) / Nat Methods by GY Lee (2007)
  8. Longva KE, Pedersen NM, Haslekås C, Stang E, Madshus IH . (2005). Herceptin-induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic down-regulation of ErbB2. Int J Cancer 116: 359–367. (10.1002/ijc.21015) / Int J Cancer by KE Longva (2005)
  9. Miljan EA, Bremer EG . (2002). Regulation of growth factor receptors by gangliosides. Sci STKE 2002: RE15. (10.1126/stke.2002.160.re15) / Sci STKE by EA Miljan (2002)
  10. Mocanu M-M, Fazekas Z, Petrás M, Nagy P, Sebestyén Z, Isola J et al. (2005). Associations of ErbB2, β1-integrin and lipid rafts on Herceptin (Trastuzumab) resistant and sensitive tumor cell lines. Cancer Lett 227: 201–212. (10.1016/j.canlet.2005.01.028) / Cancer Lett by M-M Mocanu (2005)
  11. Nagy P, Vereb G, Sebestyén Z, Horváth G, Lockett SJ, Damjanovich S et al. (2002). Lipid rafts and the local density of ErbB proteins influence the biological role of homo- and heteroassociations of ErbB2. J Cell Sci 115: 4251–4262. (10.1242/jcs.00118) / J Cell Sci by P Nagy (2002)
  12. Nahta R, Esteva FJ . (2006). Herceptin: mechanisms of action and resistance. Cancer Lett 232: 123–138. (10.1016/j.canlet.2005.01.041) / Cancer Lett by R Nahta (2006)
  13. Owens MA, Horten BC, Da Silva MM . (2004). HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 5: 63–69. (10.3816/CBC.2004.n.011) / Clin Breast Cancer by MA Owens (2004)
  14. Petersen OW, Rønnov-Jessen L, Howlett AR, Bissell MJ . (1992). Interaction with basement membrane serves to rapidly distinguish growth and differentiation pattern of normal and malignant human breast epithelial cells. Proc Natl Acad Sci USA 89: 9064–9068. (10.1073/pnas.89.19.9064) / Proc Natl Acad Sci USA by OW Petersen (1992)
  15. Pike LJ . (2006). Rafts defined: a report on the Keystone symposium on lipid rafts and cell function. J Lipid Res 47: 1597–1598. (10.1194/jlr.E600002-JLR200) / J Lipid Res by LJ Pike (2006)
  16. Razani B, Schlegel A, Liu J, Lisanti MP . (2001). Caveolin-1, a putative tumour suppressor gene. Biochem Soc Trans 29: 494–499. (10.1042/bst0290494) / Biochem Soc Trans by B Razani (2001)
  17. Ritter CA, Perez-Torres M, Rinehart C, Guix M, Dugger T, Engelman JA et al. (2007). Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res 13: 4909–4919. (10.1158/1078-0432.CCR-07-0701) / Clin Cancer Res by CA Ritter (2007)
  18. Schoenwaelder SM, Burridge K . (1999). Bidirectional signaling between the cytoskeleton and integrins. Curr Opin Cell Biol 11: 274–286. (10.1016/S0955-0674(99)80037-4) / Curr Opin Cell Biol by SM Schoenwaelder (1999)
  19. Shaw KRM, Wrobel CN, Brugge JS . (2004). Use of three-dimensional basement membrane cultures to model oncogene-induced changes in mammary epithelial morphogenesis. J Mammary Gland Biol Neoplasia 9: 297–310. (10.1007/s10911-004-1402-z) / J Mammary Gland Biol Neoplasia by KRM Shaw (2004)
  20. Shin S-I, Freedman VH, Risser R, Pollack R . (1975). Tumorigenicity of virus-transformed cells in nude mice is correlated specifically with anchorage independent growth in vitro. Proc Natl Acad Sci USA 72: 4435–4439. (10.1073/pnas.72.11.4435) / Proc Natl Acad Sci USA by S-I Shin (1975)
  21. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE et al. (1989). Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707–712. (10.1126/science.2470152) / Science by DJ Slamon (1989)
  22. Sottocornola E, Berra B, Colombo I . (2003). GM3 content modulates the EGF-activated p185c-neu levels, but not those of the constitutively activated oncoprotein p185neu. Biochim Biophys Acta 1635: 55–66. (10.1016/j.bbalip.2003.10.006) / Biochim Biophys Acta by E Sottocornola (2003)
  23. Sottocornola E, Misasi R, Mattei V, Ciarlo L, Gradini R, Garofalo T et al. (2006). Role of gangliosides in the association of ErbB2 with lipid rafts in mammary epithelial HC11 cells. FEBS J 273: 1821–1830. (10.1111/j.1742-4658.2006.05203.x) / FEBS J by E Sottocornola (2006)
  24. Timms JF, White SL, O’Hare MJ, Waterfield MD . (2002). Effects of ErbB-2 overexpression on mitogenic signalling and cell cycle progression in human breast luminal epithelial cells. Oncogene 21: 6573–6586. (10.1038/sj.onc.1205847) / Oncogene by JF Timms (2002)
  25. Wang SC, Hung MC . (2001). HER2 overexpression and cancer targeting. Semin Oncol 28: 115–124. (10.1016/S0093-7754(01)90289-1) / Semin Oncol by SC Wang (2001)
  26. Weaver VM, Lelièvre S, Lakins JN, Chrenek MA, Jones JCR, Giancotti F et al. (2002). β4 integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium. Cancer Cell 2: 205–216. (10.1016/S1535-6108(02)00125-3) / Cancer Cell by VM Weaver (2002)
  27. Wolff AC, Hammond MEH, Schwartz JN, Hagerty KL, Allred DC, Cote RJ et al. (2007). American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25: 118–145. (10.1200/JCO.2006.09.2775) / J Clin Oncol by AC Wolff (2007)
  28. Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL . (2002). Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 62: 4132–4141. / Cancer Res by FM Yakes (2002)
  29. Yamada KM, Cukierman E . (2007). Modeling tissue morphogenesis and cancer in 3D. Cell 130: 601–610. (10.1016/j.cell.2007.08.006) / Cell by KM Yamada (2007)
  30. Yarden Y . (2001). The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities. Eur J Cancer 37 (Suppl 4): S3–S8. (10.1016/S0959-8049(01)00230-1) / Eur J Cancer by Y Yarden (2001)
  31. Yaziji H, Goldstein LC, Barry TS, Werling R, Hwang H, Ellis GK et al. (2004). HER-2 testing in breast cancer using parallel tissue-based methods. JAMA 291: 1972–1977. (10.1001/jama.291.16.1972) / JAMA by H Yaziji (2004)
  32. Zhou X, Tan M, Hawthorne VS, Klos KS, Lan KH, Yang Y et al. (2004). Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin Cancer Res 10: 6779–6788. (10.1158/1078-0432.CCR-04-0112) / Clin Cancer Res by X Zhou (2004)
Dates
Type When
Created 16 years, 9 months ago (Nov. 3, 2008, 6:09 a.m.)
Deposited 3 years, 5 months ago (March 21, 2022, 12:26 p.m.)
Indexed 4 weeks, 1 day ago (Aug. 2, 2025, 12:38 a.m.)
Issued 16 years, 9 months ago (Nov. 3, 2008)
Published 16 years, 9 months ago (Nov. 3, 2008)
Published Online 16 years, 9 months ago (Nov. 3, 2008)
Published Print 16 years, 7 months ago (Jan. 22, 2009)
Funders 0

None

@article{Pickl_2008, title={Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab}, volume={28}, ISSN={1476-5594}, url={http://dx.doi.org/10.1038/onc.2008.394}, DOI={10.1038/onc.2008.394}, number={3}, journal={Oncogene}, publisher={Springer Science and Business Media LLC}, author={Pickl, M and Ries, C H}, year={2008}, month=nov, pages={461–468} }